ScinoPharm
Corporate Presentation

ScinoPharm

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm's **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

ScinoPharm

Table of Content

ScinoPharm

Overview of ScinoPharm – An API + Dossier Company

Background

- Established in 1997 in Taiwan and listed on TWSE in 2011, current market cap around US$865 million
- Major shareholders include Uni-President Group, National Development Fund, & Taiwan Sugar
- Facility & organization built in Taiwan by experienced Syntex team, received multiple regulatory inspections from US FDA, Australia, EU, Japan, etc.
- Specializes in high potent/cytotoxic APIs & moves to injectable formulations
- Expanding in China with a marketing base in Shanghai & new GMP plant in Changshu, which was inspected by US FDA with zero 483

ScinoPharm

Our Founder Team

- **Founded & managed by ex-Syntex executives**
  - **Jo Shen – Former President & CEO, 40 yrs in Chemical/Pharma industry, ex-Syntex Corporate VP of Operations**
  - **Hardy Chan – Former Executive Vice President & CSO, 40 yrs in Pharma industry, ex-Syntex VP of Research/Biotechnology**
  - **Bob Ells – Former Sr. Vice President of Operations, 45 yrs in Chemical/Pharma industry, ex-Syntex President of Manufacturing**
  - **Bob Cook – Former Sr. Vice President of Marketing and Sales, >45 yrs in Pharma industry, ex-Syntex Director of Marketing**

ScinoPharm

Business Overview

- Maintain dominant position in Specialty APIs for generic market. Strong customer base (300+) in US/EU/Japan, some through Indian generics. Aggressively developing Japan and China markets
- 71 generic APIs in current portfolio with 29 APIs approved; 60 US DMFs filed (813 DMFs WW), 33 US DMFs in oncological APIs
- 100+ NCE CRAMs projects, with 7 launched and 7 in phase III for NDA filing in 2-3 years; The Qualified Asian supplier to provide APIs to global market for multiple commercial NCEs
- Double A Strategy "API + ANDA": Focusing on Oncological & complex injectables

ScinoPharm

World Class Facilities

Taiwan

- 6.6 hectares of land, 330K sqft facilities with >200M^3 reactor volume after 2 large product lines expansion
- 5 of 16 production lines equipped with high potency capabilities for cytotoxics or steroids
- Passed US FDA, EMA, Australian TGA, Japanese PMDA inspections & 300+ CGMP audits by customers
- Provides comprehensive contract research & manufacturing services for brand drug companies
- Global Market

China

- 6.5 hectares of land with > 250M^3 reactor volume
- 3 of 7 production lines equipped with high potency capabilities for cytotoxics
- US FDA approved cGMP facility for intermediates & high potency API
- Full scope capabilities in developing and producing APIs from small to large scale for generic & CRAM markets
- Global market including China

Regulatory Inspections (API)

- US FDA inspection (7)
  - 2001/10; 2005/08; 2008/10; 2012/03; 2015/03; 2017/02; 2019/05
- Europe EMA inspection (2)
  - 2013/01; 2014/03
- Japan PMDA inspection (30)
  - On-site inspection (2) on 2008/05 and 2017/11
  - Desk inspection (28)
- EDQM Inspection (1)
  - 2016/10
- Taiwan DOH / TFDA inspection (22)
  - 2002/01; 2003/01; 2003/06; 2004/04; 2005/11; 2007/12; 2008/02; 2008/10; 2009/02; 2010/04; 2010/11; 2011/09; 2012/01; 2012/03; 2012/12; 2013/04; 2013/10; 2014/01; 2015/05; 2016/02; 2016/03;2016/06; 2017/01
- German authority HSSEN (1)
  - 2016/11
- Korea KFDA inspection (5)
  - 2008/08; 2011/02; 2015/09
  - Desk inspection (2)
- Mexico COFEPRIS inspection (4)
  - 2010/10; 2013/05; 2016/01; 2017/09

ScinoPharm

2018 Sales Distribution

By Business



By Indication



By Region



ScinoPharm

Strong Generics Product Portfolio



Note: Other (Women's Health, Gastrointestinal, Immunology and Metabolic)

ScinoPharm

Key Strengths and Strategy

Business Strategies

- Maintain balance between generic & brand business, non-competing on same product
- Provide comprehensive (lifecycle) services to NCE development companies from clinical materials to commercial
- Focus on generic APIs with high technological barrier to entry, and vertically integrated into oncology and complex injectables
- Provide low-cost R&D and manufacturing of early steps in China coupled with high quality, IP-protected GMP production in Taiwan

ScinoPharm

Competitive Advantages

- Combination of cost advantages from China & GMP/IP/EHS compliance in Taiwan
- Rich generic pipeline driven by a large & cost effective R&D infrastructure
- Familiarity with drug development & registration requirements
- Track record of timely and extensive client support
- Existence of a repeat broad & global client base

Outlook

Outlook

- **Sustain Leadership in Oncological APIs**

  Continue to launch and develop oncological injectable APIs & others with high technological barriers including Peptides

- **Establish Presences in**

  Develop API business to timely capture the generic business and CMO by MNCs

- **Japanese Market Penetration**

  Expand strategic partnerships with major pharma

- **Vertical Integration– Double A Strategy (API+ANDA)**

  Select difficult-to-make APIs to formulate dossiers for value added one-stop-shop services to customers.

ScinoPharm

Brand Quality with Asian Advantages

www.scinopharm.com

ScinoPharm